Share Market Newspaper

Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

September 15
13:38 2021
Ulcerative Colitis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Ulcerative Colitis (UC)– Pipeline Insight, 2021,” report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Ulcerative Colitis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Ulcerative Colitis pipeline landscapes. 

The report comprises Ulcerative Colitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ulcerative Colitis pipeline products.     

Some of the key takeaways from the Ulcerative Colitis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos/Gilead, Theravance Biopharma and Janssen, Arena, Landos Biopharma, etc., are developing therapies for the treatment of Ulcerative Colitis.

  • Emerging therapies such as Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Filgotinib, Izencitinib (TD-1473), Etrasimod (APD334), BT-11, are expected to have a significant impact on the  Ulcerative Colitis market in the coming years.

Get an overview of pipeline landscape @ Ulcerative Colitis Clinical Trials Analysis 

Ulcerative colitis is usually only in the innermost lining of the large intestine (colon) and rectum. Forms range from mild to severe. Having ulcerative colitis puts a patient at increased risk of developing colon cancer.

Ulcerative Colitis Pipeline Therapies along with Key Players:

  • Risankizumab (ABBV-066) by AbbVie and Boehringer Ingelheim

  • Mirikizumab (LY3074828) by Ingelheim, Eli Lilly and Company

  • Tremfya (Guselkumab) by Janssen

  • Filgotinib by Galapagos/Gilead

  • Izencitinib (TD-1473) by Theravance Biopharma and Janssen

  • Etrasimod (APD334) by Arena

  • BT-11 by Landos Biopharma

  • And others.

Scope of Ulcerative Colitis Pipeline Drug Insight

  • Coverage: Global 

  • Major Players: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos/Gilead, Theravance Biopharma and Janssen , Arena, Landos Biopharma, and others.

  • Pipeline Therapies: Risankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Filgotinib, Izencitinib (TD-1473), Etrasimod (APD334), BT-11, and others.

Table of Contents

1

Ulcerative Colitis Report Introduction

2

Ulcerative Colitis Executive Summary

3

Ulcerative Colitis Overview

4

Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment

5

Ulcerative Colitis Pipeline Therapeutics

6

Ulcerative Colitis Late Stage Products (Phase II/III)

7

Ulcerative Colitis Mid Stage Products (Phase II)

8

Ulcerative Colitis Early Stage Products (Phase I)

9

Ulcerative Colitis Preclinical Stage Products

10

Ulcerative Colitis Therapeutics Assessment

11

Ulcerative Colitis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Ulcerative Colitis Key Companies

14

Ulcerative Colitis Key Products

15

Ulcerative Colitis Unmet Needs

16 

Ulcerative Colitis Market Drivers and Barriers

17

Ulcerative Colitis Future Perspectives and Conclusion

18

Ulcerative Colitis Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Ulcerative Colitis Drugs Pipeline Report  

Related Reports:

Ulcerative Colitis Market

DelveInsight’s ‘Ulcerative Colitis-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Ulcerative Colitis Epidemiology

DelveInsight’s ‘Ulcerative Colitis Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/